

Silvio Bianchi Martini appointed as independent Member of the Board of Directors of MolMed S.p.A.

Milan (Italy), July 6, 2009 - The Board of Directors of MolMed S.p.A., pursuant to article 2386 of the Italian Civil Code, today appointed Professor Silvio Bianchi Martini as an Independent Member of the Board of Directors, as Chairman of the Internal Control Committee and as Lead Independent Director, in replacement of Professor Ferdinando Superti Furga who resigned on May 11, 2009 for personal reasons.

Silvio Bianchi Martini is full Professor of Economics at the Faculty of Economics of the University of Pisa. The Board has verified that he meets the independence and honourability requirements prescribed by regulations and by MolMed's Conduct Code, and that his offices as Director or Auditor vested in other companies do not exceed the limits identified by MolMed's specific procedure, approved by the Board on May 7, 2008.

To MolMed's knowledge, professor Silvio Bianchi Martini does not currently hold shares in the company.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies. MolMed's pipeline includes two novel therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in Phase III in high-risk acute leukaemias; NGR-hTNF, a novel vascular targeting agent (VTA), in Phase II in six different indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancers, and malignant pleural mesothelioma. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The company's shares (Milan:MLM) are listed on the Milan Stock Exchange, at the Standard segment (class I) of the MTA managed by Borsa Italiana.

For further information, please contact:

Investor Relations:

Holger Neecke
Director Business Development, IR
MolMed S.p.A.
phone: +39 02 21277.205
fax: +39 02 21277.325
e-mail: investor.relations@molmed.com

Administration, Finance & Control:

Enrico Cappelli
Chief Financial Officer
MolMed S.p.A.
phone: +39 02 21277.302
fax: +39 02 21277.325
e-mail: enrico.cappelli@molmed.com

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14.5.1999 as subsequently amended.